OIPE IAP44 MAR 21 2007 PATENT & TRADEMARK OFFICE

Docket No.: 1173-1034PUS2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Mario H. SKIADOPOULOS et al.

Application No.: 10/667,141 Confirmation No.: 7197

Filed: September 18, 2003 Art Unit: 1648

For: RECOVERY OF RECOMBINANT HUMAN PARAINFLUENZA VIRUS TYPE 2 (HPIV2) FROM CDNA AND USE OF RECOMBINANT HPIV2 IN IMMUNOGENIC COMPOSITIONS AND AS VECTORS TO ELICIT IMMUNE RESPONSES AGAINST PIV AND OTHER HUMAN PATHOGENS

Examiner: T. M. Brown

INFORMATION DISCLOSURE STATEMENT (SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08(s), attached hereto.

II. COPIES

☒ a. **Copies of cited U.S. patents and patent application publications are not included. Copies of foreign patent documents and non-patent literature are included.**

☐ b. Some or all of the documents listed on the PTO-SB08 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

☐ c. REFERENCES PREVIOUSLY CITED OR SUBMITTED - Pursuant to 37 C.F.R. §1.98(d), consideration of information listed on the PTO-SB08 form(s) is requested since any patents, publications, or other information which are listed on the PTO-SB08 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s) and U.S. Filing Date

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

☒ a. DOCUMENTS IN THE ENGLISH LANGUAGE - **The patents, publications, or other information listed on the attached PTO SB08 are in the English language and therefore, do not require a statement of relevancy.**

☐ b. DOCUMENTS NOT IN THE ENGLISH LANGUAGE - A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

☐ c. ENGLISH LANGUAGE SEARCH REPORT - An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

☐ d. OTHER - The following additional information is provided for the Examiner's consideration.

IV. FEES (check one box)

☐ a. This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

☐ b. This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

☐ c. This Information Disclosure Statement is being filed within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required. *(This section is not to be used with RCE's.)*

☐ d. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.

☐ e. This Information Disclosure Statement is being filed concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.

☐ f. This Information Disclosure Statement is being filed before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account for the fee as required by 37 C.F.R. § 1.17(p).

☒ **g. This Information Disclosure Statement is being filed before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).**

☒ **No statement; therefore, a fee as required by 37 C.F.R. § 1.17(p) is attached.**

or

☐ See the statement below. No fee is required.

V. STATEMENT UNDER 37 C.F.R. § 1.97(e)

(check only one box)

The undersigned hereby states that:

☐ a. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or

☐ b. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

☐ c. No item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.

☐ d. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VI. PAYMENT OF FEES (check one box)

☒ **The required fee is listed on the attached Fee Transmittal.**

☐ No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: March 21, 2007

Respectfully submitted,

By _____

Mark J. Nuell
Registration No.: 36,623
BIRCH, STEWART, KOLASCH & BIRCH, LLP
8110 Gatehouse Road
Suite 100 East
P.O. Box 747
Falls Church, Virginia 22040-0747
(703) 205-8000
Attorney for Applicant

Attachment(s):

☒ PTO-SB08
☒ Documents (with CD)
☐ Foreign Search Report
☒ Fees
☒ Other: Petition

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 10

Complete if Known	
Application Number	10/667,141-Conf. #7197
Filing Date	September 18, 2003
First Named Inventor	Mario H. SKIADOPOULOS
Art Unit	1648
Examiner Name	T. M. Brown
Attorney Docket Number	1173-1034PUS2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-4,683,195	07/28/1987	Mullis et al	
	AB	US-4,683,202	07/28/1987	Mullis	
	AC	US-5993,824	11/30/1999	Murphy	
	AD	US-6,264,957	07/24/2001	Collins	
	AE	US-6,140,023	06/25/2002	Durbin	
	AF	US-6,689,367	02/10/2004	Collins	
	AG	US-2004-0142448	07/22/2004	Murphy	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	BA	WO 9712032	04/03/1997			
	BB	WO 9706270	02/20/1997			
	BC	WO 9802530	01/22/1998			
	BD	WO 9853078	11/26/1998			
	BE	WO 0061611	10/19/2000			
	BF	WO 0061737	10/19/2000			
	BG	WO 0142445	06/14/2001			
	BH	WO 0104320	01/18/2001			
	BI	WO 0104335	01/18/2001			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	CA	Anderson et al., Antigenic Characterization of Respiratory Syncytial Virus Strains With Monoclonal Antibodies, Journal Infectious Diseases, Vol. 151, No. 4, 626-633 (1985)	
	CB	Baron et al., Rescue of Rinderpest Virus From Cloned cDNA, Journal of Virology, Vol. 71, No. 2, 1265-1271 (1997)	
	CC	Beeler et al., Neutralization Epitopes of F Glycoprotein of Respiratory Syncytial Virus Effect of Mutation Upon Fusion Function, Journal of Virology, Vol. 63, No. 7, 2941-2950 (1989)	
	CD	Belshe et al., Cold Adaptation of Parainfluenza Virus Type 3, Journal Medical Virology, Vol. 10(4), 235-242 (1982)	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 10

Complete if Known	
Application Number	10/667,141-Conf. #7197
Filing Date	September 18, 2003
First Named Inventor	Mario H. SKIADOPOULOS
Art Unit	1648
Examiner Name	T. M. Brown
Attorney Docket Number	1173-1034PUS2

	CE	Belshe et al., Comparison of Enzyme-Linked Immunosorbent Assay and Neutralization Techniques for Measurement of Antibody, Infection and Immunity, Vol. 37, No. 1,160-165 (1982)	
	CF	Belshe et al., Further Characterization of the Complementation Group B Temperature Sensitive Mutant of Respiratory Syncytial Virus, Journal of Virology, Vol. 24, No. 1, 8-12 (1977)	
	CG	Biacchesi et al., Recovery of NV Knockout Infectious Hematopoietic Necrosis Virus, Journal of Virology Vol. 74, No. 23, 11247-11253 (2000)	
	CH	Bilsel et al., Polymerase Errors Accumulating During Natural Evolution of the Glycoprotein Gene of Vesicular Stomatitis Virus, Journal of Virology, Vol. 64, No. 10, 4873-4883 (1990)	
	CI	Buchholz et al., Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA, Journal of Virology, Vol. 73, No. 1, 251-259 (1999)	
	CJ	Bukreyev et al., Recovery of Infectious Respiratory Syncytial Virus Expressing An Additional, Foreign Gene, Journal of Virology, Vol. 70, No. 10, 6634-6641 (1996)	
	CK	Bukreyev et al., Granulocyte-Macrophage Colony-Stimulating Factor Expressed By Recombinant Respiratory Syncytial Virus, Journal of Virology Vol. 75, No. 24, 12128-12140 (2001)	
	CL	Bukreyev et al., Interferon Expressed By A Recombinant Respiratory Syncytial Virus Attenuates Virus Replication In Mice, Proc. Natl. Acad. Sci. USA Vol. 96, 2367-2372 (1999)	
	CM	Calain et al., The Rule of Six, A Basic Feature for Efficient Replication of Sendai Virus, Journal of Virology, Vol. 67, No. 8, 4822-4830 (1993)	
	CN	Chanock et al., Parainfluenza Viruses, Fields Virology, 4th Ed., Vol. 1, 1341-1379 (2001)	
	CO	Chanock et al., Association of A New Type of Cytopathogenic Myxovirus With Infantile Croup, Journal of Experimental Medicine, Vol. 104, Plate 47, 555-577 (1956)	
	CP	Cheng et al., Effective Amplification of Long Targets From Cloned Inserts, Proc. Natl. Acad. Sci. USA, Vol. 91, 5695-5699 (1994)	
	CQ	Clarke et al, Rescue of Mumps Virus From cDNA, Journal of Virology, Vol. 74, No. 10, 4831-4838 (2000)	
	CR	Clements et al., Evaluation of Bovine Cold-Adapted Human, and Wild Type Human Parainfluenza Type 3 Viruses in Adult Volunteers, Journal of Clinical Microbiology, Vol. 29, 1175-1182 (1991)	
	CS	Coelingh et al., Antigenic and Functional Organization of Human Parainfluenza Virus Type 3 Fusion Glycoprotein, Journal of Virology, Vol. 63, No. 1, 375-382 (1989)	
	CT	Coelingh et al., Antigenic Variation in the Hemaggultinin Neuraminidase Protein of Human Parainfluenza Type 3 Virus, Virology, Vol. 143, 569-582 (1985)	
	CU	Coelingh et al., Nucleotide and Deduced Amino Acid Sequence of Hemagglutinin Neuraminidase Genes of Human Type 3 Parainfluenza Viruses, Virology, Vol. 162, 137-143 (1988)	
	CV	Collins et al., Fields Virology, Third Edition, Parainfluenza Viruses, Chapter 41, 1205-1241 (1996)	
	CW	Collins et al., Production of Infectious Human Respiratory Syncytial Virus From Cloned cDNA, Pro. Natl. Acad. Sci., Vol. 92, 11563-11567 (1995)	
	CX	Collins et al., Respiratory Syncytial Virus Reverse Genetics and Vaccine Strategies, Virology, Vol. 296 204-211 (2002)	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 10

Complete if Known	
Application Number	10/667,141-Conf. #7197
Filing Date	September 18, 2003
First Named Inventor	Mario H. SKIADOPOULOS
Art Unit	1648
Examiner Name	T. M. Brown
Attorney Docket Number	1173-1034PUS2

	CY	Connors et al., Respiratory Syncytial Virus (RSV) F, G, M2 (22K), and N Proteins Each Induce Resistance to RSV Challenge, Journal of Virology, Vol. 65, No. 3, 1634-1637 (1991)	
	CZ	Conzelmann et al., Genetic Manipulation of Non-Segmented Negative-Strand RNA Viruses, Journal of General Virology, Vol. 77, 381-389 (1996)	
	CA1	Corsoro and Pearson, Enhancing the Efficiency of DNA Mediated Gene Transfer In Mammalian Cells, Somatic Cell Genetics, Vol. 7, No. 5, 603-616 (1981)	
	CB1	Crookshanks et al., Evaluation of Cold-Adapted And Temperature-Sensitive Mutants Of Parainfluenza Virus Type 3, Journal of Medical Virology, Vol. 13, 243-249 (1984)	
	CC1	Crowe et al., Cold-Passaged, Temperature-Sensitive Mutants of Human Respiratory Syncytial Virus (RSV), Vaccine, Vol. 13, No. 9, 847-855 (1995)	
	CD1	Curran et al., Ribosomal Initiation From An ACG Condon In the Sendai Virus, EMBO Journal, Vol. 7, No. 1, 245-251 (1988)	
	CE1	Curran et al., Sendai Virus Nonstructural C Proteins Specifically Inhibit Viral mRNA Synthesis, Virology, Vol. 189, 647-656 (1992)	
	CF1	Didcock et al., The V Protein of Simian Virus 5 Inhibits Interferon Signaling By Targeting STAT1, Journal of Virology, Vol. 73, No. 12, 9928-9933 (1999)	
	CG1	Didcock et al., Sendai Virus and Simian Virus 5 Block Activation of Interferon Responsive Genes, Journal of Virology, Vol. 73, No. 4, 3125-3133 (1999)	
	CH1	Dillon et al., Expression Of Five Proteins From The Sendai Virus PC mRNA In Infected Cells, Journal of Virology, Vol. 63, No. 2, 974-977 (1989)	
	CI1	Dimock et al., Rescue of Synthetic analogs of Genomic RNA and Replicative Intermediate RNA of Human Parainfluenza Virus Type 3, Journal of Virology, Vol. 67, No. 5, 2772-2778 (1993)	
	CJ1	Duprex et al., In Vitro And In Vivo Infection Of Neural Cells By A Recombinant Measles Virus Expressing Enhanced Green Fluorescent Protein, Journal of Virology, Vol. 74, No. 17, 7972-7979 (2000)	
	CK1	Durbin et al., Comparison of the Immunogenicity and Efficacy of A Replication-Defective Vaccinia Virus, Journal of Infectious Diseases, Vol. 179, 1345-1351 (1999)	
	CL1	Durbin et al., Human Parainfluenza Virus Type 3 (PIV3) Expressing Hemagglutinin Protein of Measles Virus, Journal of Virology, Vol. 74, No. 15, 6821-6831 (2000)	
	CM1	Durbin et al., The Immunogenicity And Efficacy of Intranasally or Parenterally Administered Replication Deficient Vaccinia Parainfluenza Virus Type 3, Vaccine, Vol. 16, No. 13, 1324-1330 (1998)	
	CN1	Durbin et al., Mini. Protein Requirements for Transcription, RNA Replication of Minigenome of Human Parainfluenza Virus Type 3 and Evaluation of the Rule of Six, Virology, Vol. 234, 74-83 (1997)	
	CO1	Durbin et al., Recovery of Infections Human Parainfluenza Virus Type 3 from cDNA, Virology, Vol. 235, 323-332 (1997)	
	CP1	Durbin et al., Mutations In C, D, and V Open Reading Frames of Human Parainfluenza Virus Type 3 Attenuate Replication In Rodents and Primates, Virology, Vol. 261, 319-330 (1999)	
	CQ1	Elango et al., Human Parainfluenza Type 3 Virus Hemagglutinin-Neuraminidase Glycoprotein, Journal of Virology, Vol. 57, No. 2, 481-489 (1986)	
	CR1	Elroy-Stein et al., Cap-Independent Translation of mRNA Conferred By Encephalomyocarditis Virus 5 Sequence, Proc. Natl, Acad. Sci. USA, Vol. 86, 6126-6130 (1989)	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	4	of	10

Complete if Known	
Application Number	10/667,141-Conf. #7197
Filing Date	September 18, 2003
First Named Inventor	Mario H. SKIADOPOULOS
Art Unit	1648
Examiner Name	T. M. Brown
Attorney Docket Number	1173-1034PUS2

	CS1	Feller et al., Comparison of Identical Temperature Sensitive Mutations in the L Polymerase Proteins of Sendai and Parainfluenza3 Viruses, Virology, Vol. 276, 190-201 (2000)	
	CT1	Fenner et al., Monoclonal Antibodies Specific For Sendai Virus, Scand. Journal of Immunology, Vol. 24, 341-349 (1986)	
	CU1	Fernie et al., Classification of Hybridomas to Respiratory Syncytial Virus Glycoproteins, Proceedings of the Society for Experimental Biology and Medicine, Vol. 171, 266-271 (1982)	
	CV1	Finke et al., Ambisense Gene Expression From Recombinant Rabies Virus, Journal of Virology, Vol. 71, No. 10, 7281-7288 (1997)	
	CW1	Galinski, Annotated Nucleotide and Protein Sequences for Selected Paramyxoviridae, Nucleotide and Protein Sequences, Appendix, 537-568 (1991)	
	CX1	Garcia-Barreno et al., Oligo(A) Sequences of Human Respiratory Syncytial Virus G Protein Gene, Journal of Virology, Vol. 68, No. 9, 5460-5468 (1994)	
	CY1	Garcia-Barreno et al., Frame Shift Mutations As Novel Mechanism For Generation Of Neutralization Resistant Mutants, EMBO Journal, Vol. 9, No. 12, 4181-4187 (1990)	
	CZ1	Garcia-Sastre et al., Inhibition of Interferon Mediated Antiviral responses by Influenza A Viruses and Other Negative Strand RNA Viruses, Virology, Vol. 279, 375-384 (2001)	
	CA2	Garcin et al., A Highly Recombinogenic System For Recovery of Infectious Sendai Paramyxovirus For cDNA, EMBO Journal, Vol. 14, No. 24, 6087-6094 (1995)	
	CB2	Garcin et al., Longer And Shorter Forms Of Sendai Virus C Proteins Play Different Roles In Modulating The Cellular Antiviral Response, Journal of Virology, Vol. 75, No. 15, 6800-6807 (2001)	
	CC2	Garcin et al., All Four Sendai Virus C Proteins Bind Stst1, But Only the Larger Forms Also Induce Its Mono Ubiquitination and Degradation, Virology, Vol. 295, 256-265 (2002)	
	CD2	Gassen et al., Establishment Of A Rescue System For Canine Distemper Virus, Journal of Virology, Vol. 74, No. 22, 10737-10744 (2000)	
	CE2	Goodbourn et al., Interferons Cell Signaling, Immune Modulation, Antiviral Responses and Virus Countermeasures, Journal of General Virology, Vol. 81, 2341-2364 (2000)	
	CF2	Graham et al., A New Technique for The Assay of Infectivity of Human Adenovirus 5 DNA, Virology, Vol. 52, 456-467 (1973)	
	CG2	Griffin et al., Measles Virus, Fields Virology, Third Edition, Chapter 43, 1267-1312 (1991)	
	CH2	Haas et al., Codon Usage Limitation In The Expression Of HIV-1 Envelope Glycoprotein, Current Biology, Vol. 6, No. 3, 315-324 (1996)	
	CI2	Hall et al., Cold Passaged Human Parainfluenza Type 3 Viruses Contain ts and Non ts Mutations Leading To Attenuation In Rhesus Monkeys, Virus Research Vol. 22, 173-184 (1992)	
	CJ2	Halsey et al., Response to Measles Vaccine In Haitian Infants 6 To 12 Months Old, New England Journal of Medicine, Vol. 313, No. 9, 544-548 (1985)	
	CK2	Hasan et al., Creation of An Infectious Recombinant Sendai Virus Expressing The Firefly Luciferase Gene From The 3' Proximal First Locus, Journal of General Virology, Vol. 78, 2813-2820 (1997)	
	CL2	Hausmann et al., Paramyxovirus RNA Editing and the Requirement for Hexamer Genome Length, RNA, Vol. 2, 1033-1045 (1996)	
	CM2	Hawley-Nelson et al., A New Higher Efficiency Polycationic Liposome Transfection Reagent, Focus, Vol. 15, No. 3, 73-79 (1993)	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 10

Complete if Known	
Application Number	10/667,141-Conf. #7197
Filing Date	September 18, 2003
First Named Inventor	Mario H. SKIADOPOULOS
Art Unit	1648
Examiner Name	T. M. Brown
Attorney Docket Number	1173-1034PUS2

	CN2	He et al., Recovery of Infectious SV5 From Cloned DNA and Expression of A Foreign Gene, Virology, Vol. 237, 249-260 (1997)	
	CO2	Heikkinen et al., Prevalence of Various Respiratory Viruses In The Middle Ear During Acute Ottitis Media, New England Journal of Medicine, Vol. 340, 260-264 (1999)	
	CP2	Hoffman et al., An Infectious Clone of Human Parainfluenza Virus Type 3, Journal of Virology, Vol. 71, No. 6, 4272-4277 (1997)	
	CQ2	Huang et al., High Level Expression Of A Foreign Gene From The Most 3 Proximal Locus Of A Recombinant Newcastle Disease Virus, Journal of General Virology, Vol. 82, 1729-1736 (2001)	
	CR2	Johnson et al., Specific Targeting to CD4 Cells of Recombinant Vesicular Stomatitis Viruses Encoding Human Immunodeficiency Virus, Journal of Virology, Vol. 71, No. 7, 5060-5068 (1997)	
	CS2	Jin et al., Recombinant Human Respiratory Syncytial Virus (RSV) from cDNA and Construction of Subgroup A and B Chimeric RSV, Virology, Vol. 251, 206-214 (1998)	
	CT2	Juhasz et al., The Temperature-Sensitive (ts) Phenotype of a Cold-Passaged (cp) Live Attenuated Respiratory Syncytial Virus, Journal of Virology, Vol. 71, No. 8, 5814-5819 (1997)	
	CU2	Kahn et al., Replication Competent Or Attenuated, Nonpropagating Vesicular Stomatitis Viruses Expressing Respiratory Syncytial Virus, Journal Virology, Vol. 75, No. 22, 11079-11087 (2001)	
	CV2	Kahn et al., Recombinant Vesicular Atomatitis Virus Expressing Respiratory Syncytial Virus (RSV) Glycoproteins, Virology, Vol. 254, 81-91 (1999)	
	CW2	Karron et al., A. Live Attenuated Bovine Parainfluenza Virus Type 3 Vaccine Is Safe, Infectious, Immunogenic, and Phenotypically Stable In Infants And Children, Journal of Infectious Diseases, Vol. 171, 1107-1104 (1995)	
	CX2	Karron et al., A Live Human Parainfluenza Type 3 Virus Vaccine Is attenuated and Immunogenic In Healthy Infants and Children, Journal Infectious Diseases, Vol. 172, 1445-1450 (1995)	
	CY2	Karron et al., Evaluation of a Live Attenuated Bovine Parainfluenza Type 3 Vaccine In Two To Six Month Old Infants, Pediatric Infectious Diseases Journal, Vol. 15, 650-654 (1996)	
	CZ2	Kato et al., The Paramyxovirus, Sendai Virus, V Protein encodes A Luxury Function Required For viral Pathogenesis, EMBO Journal, Vol. 16, No. 3, 578-587 (1997)	
	CA3	Kato et al., Initiation of Sendai Virus Multiplication From Transfected cDNA or RNA with Negative or Positive Sense, Genes To Cells, Vol. 1, 569-579 (1996)	
	CB3	Kawano et al., Characterization of the Human Parainfluenza Type 2 Virus Gene Encoding the L Protein and the Intergenic Sequences, Nucleic Acids Research, Vol. 19, No. 10, 2739-2746 (1991)	
	CC3	Kawano et al., Sequence Determination of the Hemagglutinin Neuraminidase (HN) Gene of Human Parainfluenza Type 2 Virus, Virology, Vol. 174, 308-313 (1990)	
	CD3	Kawano et al., Sequence of the Fusion Protein Gene of Human Parainfluenza Type 2 Virus and Its 3 Intergenic Region, Virology, Vol. 178, 289-292 (1990)	
	CE3	Kawano et al., Complete Nucleotide Sequence of the Matrix Gene of Human Parainfluenza Type 2 Virus and Expression of the M Protein In Bacteria, Virology, Vol. 179, 857-861 (1990)	
	CF3	Kawano et al., Recovery of Infectious Human Parainfluenza Type 2 Virus From CDNA Clones and Properties of the Defective Virus, Virology, Vol. 284, 99-112 (2001)	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	6	of	10

Complete if Known	
Application Number	10/667,141-Conf. #7197
Filing Date	September 18, 2003
First Named Inventor	Mario H. SKIADOPOULOS
Art Unit	1648
Examiner Name	T. M. Brown
Attorney Docket Number	1173-1034PUS2

	CG3	Kolakofsky et al., Paramyxovirus RNA synthesis ad the Requirement for Hexamer Genome Length, Journal of Virology, Vol. 72, No. 2, 891-899 (1998)	
	CH3	Kretzschmar et al., Normal Replication of Vesicular Stomatitis Virus Without C Proteins, Virology, Vol. 216, 309-316 (1996)	
	CI3	Kretzschmar et al., High Efficiency Incorporation of Functional Influenza Virus Glycoproteins Into Recombinant Vesicular Stomatitis Viruses, Journal of Virology, Vol. 71, No. 8, 5982-5989 (1997)	
	CJ3	Krishnamurthy et al., Recovery of a Virulent Strain of Newcastle Disease Virus from Cloned CDNA, Virology, Vol. 278, 168-182 (2000	
	CK3	Kroutil et al., Exonucleolytic Proofreading During Replication of Repetitive DNA, Biochemistry, Vol. 35, 1046-1053 (1996)	
	CL3	Kulkarni et al., The Cytolytic Activity of Pulmonary CD8 Lymphocytes, Induced by Infection with a Vaccinia Virus, Journal of Virology, Vol. 67, No. 2, 1044-1049 (1993)	
	CM3	Lamb et al., Paramyxoviridae The Viruses and Their Replication, Virology, Vol. 1, No. 41, 1305-1337 (2001)	
	CN3	Latorre et al., Sendai Virus Y Proteins Are Initiated by a ribosomal Shunt, Molecular and Cellular Biology, Vol. 18, No. 9, 5021-5031 (1998)	
	CO3	Lawson et al., Recombinant Vesicular Stomatitis Viruses From DNA, Proc. Natl. Acad. Sci., Vol. 92, 4477-4481 (1995)	
	CP3	Liston et al., Ribosomal Frameshifting During Translation of Measles Virus P Protein mRNA Is Capable of Directing Synthesis, Journal of Virology, Vol. 69, No. 11, 6742-6750 (1995)	
	CQ3	Marx et al., Pediatric Hospitalizations for Croup, Journal of Infectious Diseases, Vol. 176, 1423-1427 (1997)	
	CR3	Matsuoka et al., The P Gene of Human Parainfluenza Virus Type 1 Encodes P and C Proteins But Not a Cysteine Rich V Protein, Journal of Virology, Vol. 65, No. 6, 3406-3410 (1991)	
	CS3	McGettigan et al., Expression and Immunogenicity of Human Immunodeficiency Virus Type 1 Gag Expressed By A Replication, Journal of Virology, Vol. 75, No. 18, 8724-8732 (2001)	
	CT3	McGettigan et al., Rabies Virus Based Vectors Expressing Human Immunodeficiency Virus Type 1 (HIV-1), Journal of Virology, Vol. 75, No. 9, 4430-4434 (2001)	
	CU3	Mebatsion et al., Highly Stable Expression of a Foreign Gene From Rabies Virus Vectors, Proc. Natl. Acad. Sci., Vol. 93, 7310-7314 (1996)	
	CV3	Moeller et al., Recombinant Measles Viruses Expressing Altered Hemagglutinin (H) Genes, Journal of Virology, Vol. 75, No. 16, 7612-7620 (2001)	
	CW3	Moriya et al., Large Quantity Production With Extreme Convenience of Human SDF-1 Alpha and SDF-1 Beta By a Sendai Virus Vector, FEBS Letters, Vol. 425, 105-111 (1998)	
	CX3	Mucke et al., Extragenic and Intragenic Suppression of a Transport Mutation in the Hemagglutinin Gene of an Influenza A Virus, Virology, Vol. 158, 112-117 (1987)	
	CY3	Murphy et al., Live Attenuated Virus Vaccines for Respiratory Syncytial ad Parainfluenza Viruses, Journal of Clinical Investigation, Vol. 110, 21-27 (2002)	
	CZ3	Murphy et al., An Influenza A Live Attenuated Reassortant Virus Possessing Three Temperature Sensitive Mutations in the PB2 Polymerase Gene, Vaccine, Vol. 15, No. 12, 1372-1378 (1997)	
	CA4	Murphy et al., Genome Nucleotide Lengths That Are Divisible by Six Are Not Essential but Enhance Replication, Virology, Vol. 232, 145-157 (1997)	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7 of 10

Complete if Known	
Application Number	10/667,141-Conf. #7197
Filing Date	September 18, 2003
First Named Inventor	Mario H. SKIADOPOULOS
Art Unit	1648
Examiner Name	T. M. Brown
Attorney Docket Number	1173-1034PUS2

	CB4	Murphy et al., Current Approaches to the Development of Vaccines Effective Against Parainfluenza, Virus Research, Vol. 11, 1-15 (1988)	
	CC4	Needleman and Wunsch, A General Method Applicable To The Search For Similarities In The Amino Acid Sequence Of Two Proteins, Journal of Molecular Biology, Vol. 48, 443-453 (1970)	
	CD4	Neumann et al., Gene Transfer Into Mouse Lymoa Cells By Electroporation In High Electric Fields, EMBO Journal, Vol. 1, 841-845 (1982)	
	CE4	Newman et al., Sequence Analysis of the Washington 1964 Strain of Human Parainfluenza Virus Type 1, Virus Genes, Vol. 24, 77-92 (2002)	
	CF4	Olmsted et al., Processing Surface Expression and Immunogenicity of Carboxy Terminally Truncated Mutants of G Protein, Journal Virology, Vol. 63, No. 1, 411-420 (1989)	
	CG4	Osterhaus et al., Vaccine Strategies to Overcome Maternal Antibody Mediated Inhibition of Measles Vaccine, Vaccine, Vol. 16, No. 14, 1479-1481 (1998)	
	CH4	Parisien et al., The V Protein of Human Parainfluenza Virus 2 Antagonizes Type I, Virology, Vol. 283, 230-239 (2001)	
	CI4	Pearson et al., Improved Tools For Biological Sequence Comparison, Proc. Natl. Acad. Sci. USA, Vol. 85, 2444-2448 (1988)	
	CJ4	Peeters et al., Genome Replication of Newcastls Disease Virus Involvement of the Rule of Six, Archives of Virology, Vol. 145, 1829-1845 (2000)	
	CK4	Pelet et al., Partial Characterization of a Sendai Virus Replication Promoter and the Rule of Six, Virology, Vol. 224, 405-414 (1996)	
	CL4	Perrotta et al., A Pseudoknot-Like Structure Required For Efficient Self-Cleavage Of Hepatitis Delta Virus RNA, Nature, Vol. 350, 434-436 (1991)	
	CM4	Peeters et al., Rescue Of Newcastls Disease Virus From Cloned cDNA Evidence That Cleavability Of The Fusion Protein Is A Major Determinant For Virulence, Journal of Virology, Vol. 73, No. 6, 5001-5009 (1999)	
	CN4	Polo et al., Mutational Analysis of A Virulence Locus In the E2 Glycoprotein Gene of Sindbis Virus, Journal of Virology, Vol. 65, No. 11, 6358-6361 (1991)	
	CO4	Radecke et al., Rescue of Measled Viruses from Cloned DNA, EMBO Journal, Vol. 14, 5773-5784 (1995)	
	CP4	Radecke et al., The Nonstructural C Protein Is Not Essential For Multiplication of Edmonston B Strain Measles Virus In Cultured Cells, Virology, Vol. 217, 418-421 (1996)	
	CQ4	Ray et al., Monoclonal Antibodies Reveal Extensive Antigenic Differences Between the Hemagglutinin, Virology, Vol. 148, 232-236 (1986)	
	CR4	Reed et al., Epidemiology and clinical Impact of Parainfluenza Virus Infections In Otherwise Health Infants and Young Children 5 Years Old, Journal Infectious Diseases, Vol. 175, 807-813 (1997)	
	CS4	Richardson et al., Isolation and Characterization of Further Defective Clones of Temperature Sensitive Mutant (ts-1), Archives Virology, Vol. 54, 53-60 (1977)	
	CT4	Roberts et al., Vaccination with Recombinant Vesicular Stomatitis Virus Expressing Influenza Virus Hemagglutinin, Journal Virology, Vol. 72, No. 6, 4704-4711 (1998)	
	CU4	Roberts et al., Attenuated Vesicular Stomatitis Viruses As Vaccine Vectors, Journal of Virology, Vol. 73, No. 5, 3723-3732 (1999)	
	CV4	Roberts et al., Recovery of Negative Strand RNA Viruses From Plasmid DNAs, Virology, Vol. 247, 1-6 (1998)	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 of 10

Complete if Known	
Application Number	10/667,141-Conf. #7197
Filing Date	September 18, 2003
First Named Inventor	Mario H. SKIADOPOULOS
Art Unit	1648
Examiner Name	T. M. Brown
Attorney Docket Number	1173-1034PUS2

	CW4	Rochat et al., Loss of V Protein Expression In Human Parainfluenza Virus Type 1 Is Not A Recent Event, Virus Research, Vol. 24, 137-144 (1992)	
	CX4	Rose et al., Glycoprotein exchange Vectors Based On Vesicular Stomatitis Virus, Journal of Virology, Vol. 74, No. 23, 10903-10910 (2000)	
	CY4	Rydbeck et al., Characterization of Four Parainfluenza Virus Type 3 Proteins by Use of Monoclonal Antibodies, Journal of General Virology, Vol. 67, 1531-1542 (1986)	
	CZ4	Sakai et al., Accommodation of Foreign Genes Into Sendai Virus Genome Sizes of Inserted Genes and Viral Replication, FEBS Letters, Vol. 456, 221-226 (1999)	
	CA5	Samal et al., RNA Replication By A Respiratory Syncytial Virus, Journal of Virology, Vol. 70, No. 8, 5075-5082 (1996)	
	CB5	Samuel et al., Antiviral Actions of Interferons, Clinical Microbiology Reviews, Vol. 14, No. 4, 778-809 (2001)	
	CC5	Sato et al., Characterization of Major Structural Proteins of Measles Virus with Monoclonal Antibodies, Journal of General Virology, Vol. 66, 1397-1409 (1985)	
	CD5	Schmidt et al., Recombinant Bovine Human Parainfluenza Virus Type 3 (BHPIV3), Journal of Virology, Vol. 75, No. 10, 4594-4603 (2001)	
	CE5	Schmidt et al., Bovine Parainfluenza Virus Type 3 (BPIV3) Fusion and Hemagglutinin Neuraminidase Glycoproteins, Journal of Virology, Vol. 74, 8922-8929 (2000)	
	CF5	Schneider et al., Recombinant Measles Viruses Defective for RNA Editing, Virology, Vol. 227, 314-322 (1997)	
	CG5	Schnell et al., Construction of A Novel Virus That Targets HIV-1-Infected Cells and Controls HIV-1 Infection, Cell, Vol. 90, 849-857 (1997)	
	CH5	Schnell et al., Infectious Rabies Viruses from Cloned cDNA, EMBO Journal, Vol. 13, No. 18, 4195-4203 (1994)	
	CI5	Schnell et al., The Minimal Conserved Transcription Stop Start Signal Promotes Stable Expression of A Foreign Gene, Journal Virology, Vol. 70, No. 4, 2318-2323 (1996)	
	CJ5	Schnell et al., Foreign Glycoproteins Expressed From Recombinant Vesicular Stomatitis Viruses Are Incorporated Efficiently, Proc. Natl. Acad. Sci., Vol. 93, 11359-11365 (1996)	
	CK5	Schoepp et al., Directed Mutagenesis of A Sindbis Virus Pathogenesis Site, Virology, Vol. 193, 149-159 (1993)	
	CL5	Sidhu et al., Rescue of Synthetic Measles Virus Minireplicons Measles Genomic Termini Direct, Virology, Vol. 208, 800-807 (1995)	
	CM5	Singh et al., A Recombinant Measles Virus Expressing Biologically Active Human Interleukin12, Journal of General Virology, Vol. 80, 101-106 (1999)	
	CN5	Singh et al., A Recombinant Measles Virus Expressing Hepatitis B Virus Surface Antigen Induces Humeral Immune Responses, Journal Virology, Vol. 73, No. 6, 4823-4828 (1999)	
	CO5	Skiadopoulos et al., The Bovine Papillomavirus Type 1 E2 Transactivator and Repressor Proteins Use Different Nuclear Localization Signals, Journal of Virology, Vol. 70, No. 2, 1117-1124 (1996)	
	CP5	Skiadopoulos et al., Three Amino Acid Substitutions In L Protein of Human Parainfluenza Virus Type 3 cp45 Live Attenuated Vaccine, Journal Virology, Vol. 72, No. 3, 1762-1768 (1998)	
	CQ5	Skiadopoulos et al., Identification of Mutations Contributing to Temperature Sensitive Cold Adapted, Journal Virology, Vol. 73, No. 2, 1374-1381 (1999)	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 9 of 10

Complete if Known	
Application Number	10/667,141-Conf. #7197
Filing Date	September 18, 2003
First Named Inventor	Mario H. SKIADOPOULOS
Art Unit	1648
Examiner Name	T. M. Brown
Attorney Docket Number	1173-1034PUS2

	CR5	Skiadopoulos et al., A Chimeric Human Bovine Parainfluenza Virus Type 3 Expressing Measles Virus, Journal Virology, Vol. 75, No. 21, 10498-10504 (2001)	
	CS5	Skiadopoulos et al., Generation of Parainfluenza Virus Type 1 Vaccine Candidate By Replacing HN and F Glycoproteins, Vaccine, Vol. 18, 503-510 (1999)	
	CT5	Skiadopoulos et al., Attenuation of Recombinant Human Parainfluenza Virus Type 3 cp45 Candidate Vaccine Virus, Virology, Vol. 260, 125-135 (1999)	
	CU5	Skiadopoulos et al., Long Nucleotide Insertions Between the HN and L Protein Coding Regions of Human PIV, Virology, Vol. 272, 225-234 (2000)	
	CV5	Skiadopoulos et al., Evaluation of the Replication and Immunogenicity of Recombinant Human Parainfluenza Virus Type 3 Vectors, Virology, Vol. 297, 136-152 (2002)	
	CW5	Smith & Waterman, Comparison of Biosequences, Advances In Applied Mathematics, Vol. 2, 482-489 (1981)	
	CX5	Spielhofer et al., Chimeric Measles Viruses With A Foreign Envelope, Journal of Virology, Vol. 72, No. 3, 2150-2159 (1998)	
	CY5	Stokes et al., The Complete Nucleotide Sequence of JS Strain of Human Parainfluenza Virus Type 3, Virus Research, Vol. 25, 91-103 (1992)	
	CZ5	Stokes et al., Virus Research, Erratum Vol. 27 p.96 (1993)	
	CA6	Stope et al., Chimeric Bovine Respiratory Syncytial Virus with Attachment and Fusion Glycoproteins Replaced, Journal of Virology, Vol. 75, No. 19, 9367-9377 (2001)	
	CB6	Subash et al., Recovery and Characterization of a Chimeric Rinderpest Virus with the Glycoproteins, Journal of Virology, Vol. 74, No. 19, 9039-9047 (2000)	
	CC6	Tao et al., Recovery of A Fully Viable Chimeric Human Parainfluenza Virus (PIV) Type 3, Journal Virology, Vol. 72, No. 4, 2955-2961 (1998)	
	CD6	Tao et al., Replacement of the Ectodomains of the Hemagglutinin Neuraminidase and Fusion Glycoproteins, Journal of Virology, Vol. 74, No. 14, 6448-6458 (2000)	
	CE6	Tao et al., A Live Attenuated Chimeric Recombinant Parainfluenza Virus (PIV) Encoding the Internal Proteins of PIV Type 3, Vaccine, Vol. 17, 1100-1108 (1999)	
	CF6	Tao et al., A Live Attenuated Recombinant Chimeric Parainfluenza virus (PIV) Candidate, Vaccine, Vol. 18, 1359-1366 (2000)	
	CG6	Tao et al., Construction of A Live Attenuated Bivalent Vaccine Virus Against Human Parainfluenza Virus (PIV) Types 1 and 2, Vaccine, Vol. 19, 3620-3631 (2001)	
	CH6	Tolpin et al., Genetic Factors Associated with Loss of the Temperature Sensitive Phenotype of the Influenza, Virology, Vol. 112, 505-517 (1981)	
	CI6	Treanor et al., Evaluation of the Genetic Stability of the Temperature Sensitive PB2 Gene, Journal of Virology, Vol. 68, No. 12, 7684-7688 (1994)	
	CJ6	Van Den Hoogen et al., Analysis of the Genomic Sequence of a Human Metapneumovirus, Virology, Vol. 295, 119-132 (2002)	
	CK6	Van Wyke Coelingh et al., Antigenic and Functional Organization of Human Parainfluenza Virus Type 3 Fusion Glycoprotein, Journal Virology, Vol. 63, No. 1, 375-382 (1989)	
	CL6	Van Wyke Coelingh et al., Attenuation of Bovine Parainfluenza Virus Type 3 In Nonhuman Primates, Journal Infectious Diseases, Vol. 157, No. 4, 655-662 (1988)	
	CM6	Van Wyke Coelingh et al., Antigenic and Structural Properties of Hemagglutinin Neuraminidase Glycoprotein of Human Parainfluenza Virus Type 3, Journal Virology, Vol. 61, No. 5, 1473-1477 (1987)	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

•Substitute for form 1449A/B/PTO				***Complete if Known***	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/667,141-Conf. #7197
				Filing Date	September 18, 2003
				First Named Inventor	Mario H. SKIADOPOULOS
(Use as many sheets as necessary)				Art Unit	1648
				Examiner Name	T. M. Brown
Sheet	10	of	10	Attorney Docket Number	1173-1034PUS2

	CN6	Vulliemoz et al., Rule of Six How Does the Sendai virus RNA Polymerase keep Count, Journal of Virology, Vol. 75, No. 10, 4506-4518 (2001)	
	CO6	Walsh et al., Analysis of the Respiratory Syncytial Virus Fusion Protein Using Monoclonal and Polyclonal Antibodies, Journal of General Virology, Vol. 67, 505-513 (1986)	
	CP6	Whelan et al., Efficient Recovery of Infectious Vesicular Stomatitis Virus Entirely from cDNA Clones, Proc. Natl. Acad. Sci., Vol. 92, 8388-8392 (1995)	
	CQ6	Whitehead et al., Recombinant Respiratory Syncytial Virus (RSV) Bearing A Set of Mutations, Journal Virology, Vol. 72, No. 5, 4467-4471 (1998)	
	CR6	Whitehead et al., Recombinant Respiratory Syncytial Virus Bearing A Deletion of Either the NS2 or SH Gene, Journal Virology, Vol. 73, No. 4, 3438-3442 (1999)	
	CS6	Whitehead et al., A Single Nucleotide Substitution In Transcription Start Signal of M2 Gene, Virology, Vol 247, 232-239 (1998)	
	CT6	Wigler et al., Biochemical Transfer of Single Copy Eucaryotic Genes Using Total Cellular DNA As Donor, Cell, Vol. 14, 725-731 (1978)	
	CU6	Wright et al., Evaluation of a Live Cold Passaged Temperature Sensitive Respiratory Syncytial Virus Vaccing Candidate In Infancy, Journal Infectious Diseases, Vol. 182, 1331-1342 (2000)	
	CV6	Wyatt et al. Replication Deficient Vaccinia Virus Encoding Bacteriophage T7 RNA, Virology, Vol. 210, 202-205 (1995)	
	CW6	Yu et al., Sendai Virus Based Expression of HIV-a gp120 Reinforcement By The V- Version, Genes to Cells, Vol. 2, 457-466 (1997)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	